Recombinant Human SLAMF6 protein
Be the first to review this product! Submit a review
|
(0 Publication)
Recombinant Human SLAMF6 protein is a Human Fragment protein, in the 28 to 225 aa range, expressed in HEK 293 cells, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, HPLC.
View Alternative Names
CD352, KALI, UNQ6123/PRO20080, SLAMF6, SLAM family member 6, Activating NK receptor, NK-T-B-antigen, NTB-A
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
SLAMF6 assists in modulating immune cell interactions and is part of specific receptor complexes. It influences the activation and proliferation of immune cells and contributes to the maintenance of immune homeostasis. SLAMF6 interacts with signaling pathways involving SAP (SLAM-associated protein) and EAT-2 which facilitate downstream signaling events essential for immune cell function and communication.
Pathways
SLAMF6 integrates within the SLAM receptor signaling pathway impacting the regulation of immune responses. It plays a role in the NF-kB signaling pathway important for inflammatory and immune responses. Related proteins in these pathways include SAP and EAT-2 important in signal transduction cascades that affect cell survival differentiation and function of immune cells.
Specifications
Form
Lyophilized
Additional notes
ab151940 has a purity greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE. 0.2 µM filtered.
General info
Function
Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors (PubMed : 11489943, PubMed : 16920955). Positive signaling in NK cells implicates phosphorylation of VAV1. NK cell activation seems to depend on SH2D1B and not on SH2D1A (PubMed : 16920955). In conjunction with SLAMF1 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage (By similarity). Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed : 16920955, PubMed : 22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed : 22989874). In conjunction with SLAMF1 and CD84/SLAMF5 may be a negative regulator of the humoral immune response. In the absence of SH2D1A/SAP can transmit negative signals to CD4(+) T-cells and NKT cells. Negatively regulates germinal center formation by inhibiting T-cell : B-cell adhesion; the function probably implicates increased association with PTPN6/SHP-1 via ITSMs in absence of SH2D1A/SAP. However, reported to be involved in maintaining B-cell tolerance in germinal centers and in preventing autoimmunity (By similarity).
Post-translational modifications
Phosphorylation in NK cells upon engagment by SLAMF6-expressing target cells is leading to receptor activation.
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com